Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concomitant Tdap and MenACWY-CRM Vaccine in Healthy Subjects Aged 11-25 Years
NCT00329901Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Primary completion
- May 2007
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Meningococcal A, C, Y and W-135 conjugate vaccine, tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in meningococcal disease, Tetanus, diphtheria, pertussis, sponsored by Novartis. Started Apr 2006; status: completed.
02
Drugs
Meningococcal A, C, Y and W-135 conjugate vaccinetetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine
03
Conditions
meningococcal diseaseTetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT00329901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329901.